Company Confirms FY26 Adjusted EBITDA View of $37M-$49M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Should l Buy MYGN?
Backs FY26 adjusted EBITDA view $37M-$49M. Backs FY26 gross margin view 68%-69%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 3.620
Low
4.00
Averages
7.38
High
9.00
Current: 3.620
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing
- Collaborative Awareness Campaign: Myriad Genetics has partnered with actress Jackie Tohn to raise awareness about the significance of the MyRisk® Hereditary Cancer Test, particularly after Tohn discovered her BRCA1 gene variant, enabling proactive health management.
- Risk Assessment Insights: Tohn learned through genetic testing that she had an 85% risk of developing breast cancer and a 65% risk of ovarian cancer, underscoring the critical role of hereditary cancer screening in early detection and prevention, potentially saving lives.
- Comprehensive Testing Scope: The MyRisk® test evaluates 63 genes across 11 cancer types, with its breast cancer risk assessment being twice as predictive as personal and family history alone, highlighting its importance in precision medicine.
- Clinical Relevance: More than one in four women in OB-GYN settings meet the clinical criteria for hereditary cancer testing, with Ashkenazi Jewish individuals having a 1 in 40 chance of carrying BRCA1/2 mutations, emphasizing the need for targeted testing in specific populations.
See More
Myriad Genetics Reports Q1 2026 Earnings Miss
- Earnings Miss: Myriad Genetics reported Q1 2026 revenue of $200.4 million, falling short of expectations by approximately $2 million, despite a 2% year-over-year growth, which could not offset the impact of stable test volumes, leading to a nearly 20% drop in stock price.
- Mixed Business Growth: The Cancer Care and Mental Health units achieved year-over-year test volume growth of 13% and 7%, generating revenues of $120.2 million and $38.3 million respectively, indicating strong performance in these areas; however, Prenatal Health test volumes declined by about 12%, resulting in a 15% drop in product revenue.
- Slight Margin Decline: Although the adjusted gross margin decreased from 69.0% to 68.8%, the adjusted loss per share reached $0.09, tripling from the previous year and exceeding consensus by $0.02, reflecting challenges in cost management.
- Reaffirmed Outlook: CEO Sam Raha noted decisive steps taken to address the Prenatal Health business, expecting improved performance in the latter half of 2026, while reaffirming the revenue outlook of $860 million to $880 million for 2026, demonstrating confidence in future performance.
See More
Myriad Genetics Q1 2026 Earnings Call Insights
- Revenue Performance: Myriad Genetics reported Q1 2026 revenue of $200.4 million, which, while meeting expectations, reflects only a 2% year-over-year growth, indicating increasing market pressures that may affect future investment confidence.
- Test Result Growth: The company delivered 385,000 test results in Q1, with hereditary cancer testing growing by 10% and 16% in affected and unaffected populations respectively, demonstrating strong demand in specific market segments.
- Financial Outlook: Management reaffirmed full-year 2026 revenue guidance of $860 million to $880 million, expecting low single-digit growth in Q2 and acceleration thereafter, reflecting confidence in the expanded sales team's contributions.
- Investment and Spending: The company plans to invest $35 million over the next several years to enhance commercial capabilities and has expanded its sales team by over 100 executives, a move aimed at supporting revenue growth in the second half, but it also led to a Q1 adjusted EBITDA loss of $5 million.
See More
Myriad Genetics Q1 Results: Revenue Growth Amid Wider Losses
- Revenue Growth: Myriad Genetics reported a revenue of $200.4 million for Q1 2026, slightly up from $195.9 million a year earlier, indicating stability in the company's market position.
- Widening Losses: Despite the revenue increase, the net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter, highlighting increased cost pressures faced by the company.
- Increased Operating Loss: The operating loss rose to $30.7 million, up from $29.0 million last year, primarily due to total operating expenses increasing from $163.2 million to $168.3 million, reflecting higher spending on R&D and marketing.
- Stock Price Decline: MYGN's after-hours trading saw a drop of $0.56, or 11.13%, on Nasdaq, reflecting investor concerns regarding the company's financial performance.
See More
Myriad Genetics Q1 Earnings Miss Expectations
- Disappointing Earnings: Myriad Genetics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating pressure on profitability that may affect investor confidence moving forward.
- Lackluster Revenue Growth: The company generated $200.4 million in revenue for the quarter, a 2.2% year-over-year increase, yet fell short of expectations by $2.04 million, reflecting weaker-than-anticipated market demand that could hinder future business development.
- Test Volume Variability: Test volumes in Cancer Care and Mental Health grew by 13% and 7% year-over-year, respectively, while Prenatal Health saw a 12% decline, highlighting performance disparities across different business segments that may necessitate strategic adjustments.
- 2026 Guidance: Myriad reiterated its FY 2026 revenue guidance of $860 million to $880 million, with expectations that second-half revenue will exceed the first half, indicating cautious optimism from management, though ongoing market dynamics will need to be monitored closely.
See More
Myriad Genetics to Announce Q1 Earnings on May 5th
- Earnings Announcement: Myriad Genetics (MYGN) is set to release its Q1 earnings report on May 5th after market close, with a consensus EPS estimate of -$0.07, reflecting a significant year-over-year decline of 133.3%, indicating potential profitability challenges ahead.
- Revenue Expectations: The anticipated revenue for Q1 stands at $202.44 million, representing a modest year-over-year growth of 3.3%, suggesting some market demand despite overall sluggish growth in the competitive genetic testing sector.
- Historical Performance: Over the past two years, MYGN has surpassed EPS and revenue estimates 88% of the time, although in the last three months, EPS estimates have seen one upward revision and nine downward revisions, indicating analyst divergence regarding the company's future performance.
- Future Outlook: Myriad Genetics has set a revenue target of $860 million to $880 million for 2026, demonstrating confidence in its cancer care continuum strategy, even as it navigates current challenges in the market.
See More
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing
- Collaborative Awareness Campaign: Myriad Genetics has partnered with actress Jackie Tohn to raise awareness about the significance of the MyRisk® Hereditary Cancer Test, particularly after Tohn discovered her BRCA1 gene variant, enabling proactive health management.
- Risk Assessment Insights: Tohn learned through genetic testing that she had an 85% risk of developing breast cancer and a 65% risk of ovarian cancer, underscoring the critical role of hereditary cancer screening in early detection and prevention, potentially saving lives.
- Comprehensive Testing Scope: The MyRisk® test evaluates 63 genes across 11 cancer types, with its breast cancer risk assessment being twice as predictive as personal and family history alone, highlighting its importance in precision medicine.
- Clinical Relevance: More than one in four women in OB-GYN settings meet the clinical criteria for hereditary cancer testing, with Ashkenazi Jewish individuals having a 1 in 40 chance of carrying BRCA1/2 mutations, emphasizing the need for targeted testing in specific populations.
See More
Myriad Genetics Reports Q1 2026 Earnings Miss
- Earnings Miss: Myriad Genetics reported Q1 2026 revenue of $200.4 million, falling short of expectations by approximately $2 million, despite a 2% year-over-year growth, which could not offset the impact of stable test volumes, leading to a nearly 20% drop in stock price.
- Mixed Business Growth: The Cancer Care and Mental Health units achieved year-over-year test volume growth of 13% and 7%, generating revenues of $120.2 million and $38.3 million respectively, indicating strong performance in these areas; however, Prenatal Health test volumes declined by about 12%, resulting in a 15% drop in product revenue.
- Slight Margin Decline: Although the adjusted gross margin decreased from 69.0% to 68.8%, the adjusted loss per share reached $0.09, tripling from the previous year and exceeding consensus by $0.02, reflecting challenges in cost management.
- Reaffirmed Outlook: CEO Sam Raha noted decisive steps taken to address the Prenatal Health business, expecting improved performance in the latter half of 2026, while reaffirming the revenue outlook of $860 million to $880 million for 2026, demonstrating confidence in future performance.
See More
Myriad Genetics Q1 2026 Earnings Call Insights
- Revenue Performance: Myriad Genetics reported Q1 2026 revenue of $200.4 million, which, while meeting expectations, reflects only a 2% year-over-year growth, indicating increasing market pressures that may affect future investment confidence.
- Test Result Growth: The company delivered 385,000 test results in Q1, with hereditary cancer testing growing by 10% and 16% in affected and unaffected populations respectively, demonstrating strong demand in specific market segments.
- Financial Outlook: Management reaffirmed full-year 2026 revenue guidance of $860 million to $880 million, expecting low single-digit growth in Q2 and acceleration thereafter, reflecting confidence in the expanded sales team's contributions.
- Investment and Spending: The company plans to invest $35 million over the next several years to enhance commercial capabilities and has expanded its sales team by over 100 executives, a move aimed at supporting revenue growth in the second half, but it also led to a Q1 adjusted EBITDA loss of $5 million.
See More
Myriad Genetics Q1 Results: Revenue Growth Amid Wider Losses
- Revenue Growth: Myriad Genetics reported a revenue of $200.4 million for Q1 2026, slightly up from $195.9 million a year earlier, indicating stability in the company's market position.
- Widening Losses: Despite the revenue increase, the net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter, highlighting increased cost pressures faced by the company.
- Increased Operating Loss: The operating loss rose to $30.7 million, up from $29.0 million last year, primarily due to total operating expenses increasing from $163.2 million to $168.3 million, reflecting higher spending on R&D and marketing.
- Stock Price Decline: MYGN's after-hours trading saw a drop of $0.56, or 11.13%, on Nasdaq, reflecting investor concerns regarding the company's financial performance.
See More
Myriad Genetics Q1 Earnings Miss Expectations
- Disappointing Earnings: Myriad Genetics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating pressure on profitability that may affect investor confidence moving forward.
- Lackluster Revenue Growth: The company generated $200.4 million in revenue for the quarter, a 2.2% year-over-year increase, yet fell short of expectations by $2.04 million, reflecting weaker-than-anticipated market demand that could hinder future business development.
- Test Volume Variability: Test volumes in Cancer Care and Mental Health grew by 13% and 7% year-over-year, respectively, while Prenatal Health saw a 12% decline, highlighting performance disparities across different business segments that may necessitate strategic adjustments.
- 2026 Guidance: Myriad reiterated its FY 2026 revenue guidance of $860 million to $880 million, with expectations that second-half revenue will exceed the first half, indicating cautious optimism from management, though ongoing market dynamics will need to be monitored closely.
See More
Myriad Genetics to Announce Q1 Earnings on May 5th
- Earnings Announcement: Myriad Genetics (MYGN) is set to release its Q1 earnings report on May 5th after market close, with a consensus EPS estimate of -$0.07, reflecting a significant year-over-year decline of 133.3%, indicating potential profitability challenges ahead.
- Revenue Expectations: The anticipated revenue for Q1 stands at $202.44 million, representing a modest year-over-year growth of 3.3%, suggesting some market demand despite overall sluggish growth in the competitive genetic testing sector.
- Historical Performance: Over the past two years, MYGN has surpassed EPS and revenue estimates 88% of the time, although in the last three months, EPS estimates have seen one upward revision and nine downward revisions, indicating analyst divergence regarding the company's future performance.
- Future Outlook: Myriad Genetics has set a revenue target of $860 million to $880 million for 2026, demonstrating confidence in its cancer care continuum strategy, even as it navigates current challenges in the market.
See More
